摘要
研究丝裂原活化蛋白激酶(mitogen activated protein kinase,MAPK)相关蛋白丝裂原活化蛋白激酶磷酸酶(mitogen activated protein kinase phosphatase-1,MKP-1)和磷酸化细胞外信号调节激酶(phosphorylation extracellular signal-regulated kinases,p-ERK1/2)在上皮性卵巢肿瘤组织及正常卵巢组织中的表达差异,并探讨其在卵巢癌发生、发展中的作用,为卵巢癌的治疗提供新的思路及实验依据。选取64例上皮性卵巢癌、35例卵巢上皮性交界瘤及32例卵巢上皮性良性肿瘤患者的组织,另选取26例正常卵巢组织作对照,进行MKP-1及p-ERK1/2的免疫组化分析,并同时对其中部分病例进行上述蛋白的western-blot研究。结果显示正常卵巢、良性肿瘤、交界瘤及卵巢癌组织MKP-1的表达依次递减,各组之间进行两两比较均有显著性差异(P<0.01),FIGOⅢ期与Ⅳ期卵巢癌组织MKP-1的表达显著低于Ⅰ期与Ⅱ期卵巢癌组织(P<0.01);而p-ERK1/2在正常卵巢、良性肿瘤、交界瘤及卵巢癌组织的表达依次递增,各组之间进行两两比较也均有显著性差异(P<0.01),FIGOⅢ期与Ⅳ期卵巢癌组织p-ERK1/2的表达显著高于Ⅰ期与Ⅱ期卵巢癌组织(P<0.01)。且免疫组化及western-blot均显示MKP-1与p-ERK1/2在卵巢癌组织中的表达存在显著的负相关性,(r=-0.90,P<0.01及r=-0.78,P<0.01)。本研究结果表明MKP-1与p-ERK1/2的异常表达可能跟上皮性卵巢肿瘤的发生、发展有关,它们之间的表达失衡可能是卵巢癌发生、发展的原因之一。
To investigate the expression of mitogen activated protein kinase phosphatase-1 （MKP-1） and phosphorylation extracellular signal-regulated kinases （p-ERK1/2） in primary ovarian epithelial tumor tissues, and provide experiment＇s foundation on the new treatment in ovarian cancer. Expression of MKP-1 and p-ERK1/2 in tissues from 64 patients with primary ovarian epithelial tumor, 35 patients with ovarian epithelial bordline tumor, 32 patients with ovarian epithelial benign tumor and 26 normal ovarian tissues was detected by immunohistochemistry. Western-blot was also used for detecting the expression of MKP-1 and p-ERK1/2 protein in these tissues. Immunohistochemistry and Western-blot assay showed that the expression of MKP-1 was gradually decreased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were significant differences among them （P〈0.01）. The MKP-1 expression level in the carcinoma tissues of stage Ⅲ/Ⅳ patients was significantly lower than that of stage Ⅰ/Ⅱ patients. However, the expression of p-ERK1/2 was gradually increased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were also significant differences among them （P〈0.01）, the p-ERKlr2 expression level in the carcinoma tissues of stage Ⅲ/Ⅳ patients was significantly higher than that of stage Ⅰ/Ⅱ patients. Expression of MKP-1 and p-ERK1/2 in same ovarian carcinoma tissues detected by immunohistochemistry and Western-blot assay showed significant negative correlation （r=-0.90, P〈0.01 and r=-0.78, P〈0.01 respectively）. The expression changes of MKP-1 and ERKs may play a role in the development of ovarian carcinoma. The abnormal expression of MKP-1 and p-ERK1/2 probably assists in promoting the development and progression of ovarian carcinoma.
出处
《分子细胞生物学报》
CSCD
北大核心
2009年第3期224-230,共7页
Journal of Molecular Cell Biology
基金
浙江省自然科学基金资助(项目编号Y206246)~~
